|
September 10, 2024
|
Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024
|
|
|
September 5, 2024
|
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
|
|
|
July 1, 2024
|
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
|
|
|
June 12, 2024
|
Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
|
|
June 12, 2024
|
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
|
|
|
May 22, 2024
|
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
|
|
|
May 7, 2024
|
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
|
|
|
April 16, 2024
|
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
|
|
|
March 19, 2024
|
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
|
|
|
February 12, 2024
|
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
|
|
